Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07223749 · ClinicalTrials.gov registry record

Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm

A clinical trial of COPD (Chronic Obstructive Pulmonary Disease), sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT07223749: Recruiting study of COPD (Chronic Obstructive Pulmonary Disease), sponsored by Wake Forest University Health Sciences.

NCT07223749 is a study of COPD (Chronic Obstructive Pulmonary Disease) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 500 participants, below the 679-participant average among 9 other COPD (Chronic Obstructive Pulmonary Disease) trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07223749, a study of COPD (Chronic Obstructive Pulmonary Disease), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

Under-diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is prevalent, with an estimated 75% of adults suffering from COPD in the US, without clinical recognition. Often, the first diagnosis of COPD comes with a flare or exacerbation. In one study, 34% of patients were first diagnosed during hospitalization for an exacerbation, an event associated with a 1-year mortality rate of 26%. When COPD is finally diagnosed, it is often in the late stages, with an average lung function of 50% of normal. Conversely, COPD can be over-diagnosed, defined as symptoms in an individual without airflow obstruction. Over-diagnosed people have significantly higher rates of hospitalization, ER visits, and ambulatory care visits because individuals are treated for a disorder they don't have and are not being treated for the disorder they do have. Lack of diagnostic clarity places patients at risk of medication complications without potential benefit. Conversely, failure to diagnose preempts the benefits of therapy. To date, no reliable solution has been found to address this problem.

Primary Outcome

prospectively evaluate our tool on a population of patients regardless of underlying COPD risk - It will be an analysis using the algorithm developed by Dr. Wells of the percentage of subjects who demonstrated obstructive airway disease

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-08-22
Est. Completion 2026-12-30
Wake Forest University Health Sciences

1,140 total trials

What NCT07223749 shows while recruiting

NCT07223749 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 679-participant average among 9 other COPD (Chronic Obstructive Pulmonary Disease) trials with a reported enrollment target (26% lower).

The record links to 1 condition, with COPD (Chronic Obstructive Pulmonary Disease) appearing as the primary indexed condition, and to 0 interventions.

NCT07223749 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT07223749 about?

NCT07223749 is a clinical study titled "Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm". Under-diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is prevalent, with an estimated 75% of adults suffering from COPD in the US, without clinical recognition. Often, the first diagnosis of COPD comes with a flare or exacerbation. In one study, 34% of patients were first diagnosed during ...

What is the current status of trial NCT07223749?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-08-22. Estimated completion is 2026-12-30.

What conditions does trial NCT07223749 study?

This clinical trial studies the following conditions: COPD (Chronic Obstructive Pulmonary Disease).

Who is sponsoring clinical trial NCT07223749?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07223749 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD (Chronic Obstructive Pulmonary Disease)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07223749's enrollment target sits among peer trials

500 2nd of 9 the highest of 9 other COPD (Chronic Obstructive Pulmonary Disease) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COPD (Chronic Obstructive Pulmonary Disease) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07223749, the US trial registry maintained by the National Library of Medicine. NCT07223749 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.